Catherine M. Crespi

Catherine M. Crespi

Auto-generated profile, based on publicly available information

Catherine M. Crespi

University of California, Los Angeles

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2014 in Cancer
Verified
Journal Article
Open access
PDF file
JBJulienne E. Bower
Julienne E. Bower
ACAlexandra D. Crosswell
Alexandra D. Crosswell
ASAnnette L. Stanton
Annette L. Stanton
CCCatherine M. Crespi
Catherine M. Crespi
DWDiana Winston
Diana Winston
PGPatricia A. Ganz
Patricia A. Ganz
BACKGROUND: Premenopausal women diagnosed with breast cancer are at risk for psychological and behavioral disturbances after cancer treatment. Targeted interventions are needed to address the needs of this vulnerable group.METHODS: This randomized trial provided the first evaluation of a brief, mindfulness‐based intervention for younger breast cancer survivors designed to reduce stress, depression, and inflammatory activity. Women diagnosed with early stage breast cancer at or before age 50 who had completed cancer treatment were randomly assigned to a 6‐week Mindful Awareness Practices (MAPS) intervention group (n = 39) or to a wait‐list control group (n = 32). Participants completed questionnaires before and after the intervention to assess stress and depressive symptoms (primary outcomes) as well as physical symptoms, cancer‐related distress, and positive outcomes. Blood samples were collected to examine genomic and circulating markers of inflammation. Participants also completed questionnaires at a 3‐month follow‐up assessment.RESULTS: In linear mixed models, the MAPS intervention led to significant reductions in perceived stress (P = .004) and marginal reductions in depressive symptoms (P = .094), as well as significant reductions in proinflammatory gene expression (P = .009) and inflammatory signaling (P = .001) at postintervention. Improvements in secondary outcomes included reduced fatigue, sleep disturbance, and vasomotor symptoms and increased peace and meaning and positive affect (P < .05 for all). Intervention effects on psychological and behavioral measures were not maintained at the 3‐month follow‐up assessment, although reductions in cancer‐related distress were observed at that assessment.CONCLUSIONS: A brief, mindfulness‐based intervention demonstrated preliminary short‐term efficacy in reducing stress, behavioral symptoms, and proinflammatory signaling in younger breast cancer survivors. Cancer 2015;121:1231–1240. © 2014 American Cancer Society.

29 January 2018 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Open access
PDF file
Marco VincetiMarco Vinceti
Marco Vinceti
TFTommaso Filippini
Tommaso Filippini
CGCinzia Del Giovane
Cinzia Del Giovane
GDGabriele Dennert
Gabriele Dennert
MZMarcel Zwahlen
Marcel Zwahlen
CCCatherine M Crespi
Catherine M Crespi
Background This review is the third update of the Cochrane review "Selenium for preventing cancer". Selenium is a naturally occurring element with both nutritional and toxicological properties. Higher selenium exposure and selenium supplements have been suggested to protect against several types of cancer. Objectives To gather and present evidence needed to address two research questions: 1. What is the aetiological relationship between selenium exposure and cancer risk in humans? 2. Describe the efficacy of selenium supplementation for cancer prevention in humans. Search methods We updated electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 2), MEDLINE (Ovid, 2013 to January 2017, week 4), and Embase (2013 to 2017, week 6), as well as searches of clinical trial registries. Selection criteria We included randomised controlled trials (RCTs) and longitudinal observational studies that enrolled adult participants. Data collection and analysis We performed random‐effects (RE) meta‐analyses when two or more RCTs were available for a specific outcome. We conducted RE meta‐analyses when five or more observational studies were available for a specific outcome. We assessed risk of bias in RCTs and in observational studies using Cochrane's risk assessment tool and the Newcastle‐Ottawa Scale, respectively. We considered in the primary analysis data pooled from RCTs with low risk of bias. We assessed the certainty of evidence by using the GRADE approach. Main results We included 83 studies in this updated review: two additional RCTs (10 in total) and a few additional trial reports for previously included studies. RCTs involved 27,232 participants allocated to either selenium supplements or placebo. For analyses of RCTs with low risk of bias, the summary risk ratio (RR) for any cancer incidence was 1.01 (95% confidence interval (CI) 0.93 to 1.10; 3 studies, 19,475 participants; high‐certainty evidence). The RR for estimated cancer mortality was 1.02 (95% CI 0.80 to 1.30; 1 study, 17,444 participants). For the most frequently investigated site‐specific cancers, investigators provided little evidence of any effect of selenium supplementation. Two RCTs with 19,009 participants indicated that colorectal cancer was unaffected by selenium administration (RR 0.99, 95% CI 0.69 to 1.43), as were non‐melanoma skin cancer (RR 1.16, 95% CI 0.30 to 4.42; 2 studies, 2027 participants), lung cancer (RR 1.16, 95% CI 0.89 to 1.50; 2 studies, 19,009 participants), breast cancer (RR 2.04, 95% CI 0.44 to 9.55; 1 study, 802 participants), bladder cancer (RR 1.07, 95% CI 0.76 to 1.52; 2 studies, 19,009 participants), and prostate cancer (RR 1.01, 95% CI 0.90 to 1.14; 4 studies, 18,942 participants). Certainty of the evidence was high for all of these cancer sites, except for breast cancer, which was of moderate certainty owing to imprecision, and non‐melanoma skin cancer, which we judged as moderate certainty owing to high heterogeneity. RCTs with low risk of bias suggested increased melanoma risk. Results for most outcomes were similar when we included all RCTs in the meta‐analysis, regardless of risk of bias. Selenium supplementation did not reduce overall cancer incidence (RR 0.99, 95% CI 0.86 to 1.14; 5 studies, 21,860 participants) nor mortality (RR 0.81, 95% CI 0.49 to 1.32; 2 studies, 18,698 participants). Summary RRs for site‐specific cancers showed limited changes compared with estimates from high‐quality studies alone, except for liver cancer, for which results were reversed. In the largest trial, the Selenium and Vitamin E Cancer Trial, selenium supplementation increased risks of alopecia and dermatitis, and for participants with highest background selenium status, supplementation also increased risk of high‐grade prostate cancer. RCTs showed a slightly increased risk of type 2 diabetes associated with supplementation. A hypothesis generated by the Nutritional Prevention of Cancer Trial ‐ that individuals with low blood selenium levels could reduce their risk of cancer (particularly prostate cancer) by increasing selenium intake ‐ has not been confirmed. As RCT participants have been overwhelmingly male (88%), we could not assess the potential influence of sex or gender. We included 15 additional observational cohort studies (70 in total; over 2,360,000 participants). We found that lower cancer incidence (summary odds ratio (OR) 0.72, 95% CI 0.55 to 0.93; 7 studies, 76,239 participants) and lower cancer mortality (OR 0.76, 95% CI 0.59 to 0.97; 7 studies, 183,863 participants) were associated with the highest category of selenium exposure compared with the lowest. Cancer incidence was lower in men (OR 0.72, 95% CI 0.46 to 1.14, 4 studies, 29,365 men) than in women (OR 0.90, 95% CI 0.45 to 1.77, 2 studies, 18,244 women). Data show a decrease in risk of site‐specific cancers for stomach, colorectal, lung, breast, bladder, and prostate cancers. However, these studies have major weaknesses due to study design, exposure misclassification, and potential unmeasured confounding due to lifestyle or nutritional factors covarying with selenium exposure beyond those taken into account in multi‐variable analyses. In addition, no evidence of a dose‐response relation between selenium status and cancer risk emerged. Certainty of evidence was very low for each outcome. Some studies suggested that genetic factors might modify the relation between selenium and cancer risk ‐ an issue that merits further investigation. Authors' conclusions Well‐designed and well‐conducted RCTs have shown no beneficial effect of selenium supplements in reducing cancer risk (high certainty of evidence). Some RCTs have raised concerns by reporting a higher incidence of high‐grade prostate cancer and type 2 diabetes in participants with selenium supplementation. No clear evidence...

1 September 2012 in Contemporary Clinical Trials
Verified
Journal Article
Closed access
SWSheng Wu
Sheng Wu
CCCatherine M. Crespi
Catherine M. Crespi
WWWeng Kee Wong
Weng Kee Wong

28 September 2010 in British Journal of Cancer
Verified
Journal Article
Open access
Leeka KheifetsLeeka Kheifets
Leeka Kheifets
AAA Ahlbom
A Ahlbom
CCC M Crespi
C M Crespi
GDG Draper
G Draper
JHJ Hagihara
J Hagihara
VFV Wunsch Filho
V Wunsch Filho
Background: Methods: Results: Conclusions:

1 January 2013 in Science of The Total Environment
Verified
Journal Article
Closed access
Marco VincetiMarco Vinceti
Marco Vinceti
CCCatherine M. Crespi
Catherine M. Crespi
FBFrancesca Bonvicini
Francesca Bonvicini
CMCarlotta Malagoli
Carlotta Malagoli
Margherita FerranteMargherita Ferrante
Margherita Ferrante
SSSaverio Stranges
Saverio Stranges

1 September 2013 in NeuroToxicology
Verified
Journal Article
Open access
Marco VincetiMarco Vinceti
Marco Vinceti
Nikolay SolovyevNikolay Solovyev
Nikolay Solovyev
JESSICA MANDRIOLIJESSICA MANDRIOLI
JESSICA MANDRIOLI
CCCatherine M. Crespi
Catherine M. Crespi
FBFrancesca Bonvicini
Francesca Bonvicini
BMBernhard Michalke
Bernhard Michalke
Exposure to selenium, and particularly to its inorganic forms, has been hypothesized as a risk factor for amyotrophic lateral sclerosis (ALS), a fast progressing motor neuron disease with poorly understood etiology. However, no information is known about levels of inorganic and some organic selenium species in the central nervous system of ALS patients, and recent observations suggest that peripheral biomarkers of exposure are unable to predict these levels for several Se species including the inorganic forms. Using a hospital-referred case-control series and advanced selenium speciation methods, we compared the chemical species of selenium in cerebrospinal fluid from 38 ALS patients to those of 38 reference neurological patients matched on age and gender. We found that higher concentrations of inorganic selenium in the form of selenite and of human serum albumin-bound selenium were associated with increased ALS risk (relative risks 3.9 (95% confidence interval 1.2-11.0) and 1.7 (1.0-2.9) for 0.1μg/L increase). Conversely, lower concentrations of selenoprotein P-bound selenium were associated with increased risk (relative risk 0.2 for 1μg/L increase, 95% confidence interval 0.04-0.8). The associations were stronger among cases age 50 years or older, who are postulated to have lower rates of genetic disease origin. These results suggest that excess selenite and human serum albumin bound-selenium and low levels of selenoprotein P-bound selenium in the central nervous system, which may be related, may play a role in ALS etiology.